COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide
COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide
Active, not recruiting · NCT05434689 · Registry updated 2026-06-01Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 1 / Phase 2 | 2026-06-01 | NCT05434689 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Bristol-Myers Squibb | 422 |
| coMMit Myeloma Trials | 1 |
| University of Alabama at Birmingham | 467 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Ohio State University Medical College | Columbus | United States | 1 |
| Oregon Health and Science University | Portland | United States | 382 |
| University of Alabama at Birmingham | Birmingham | United States | 193 |
| University of Wisconsin | Madison | United States | 64 |